Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease

• Status: Completed
• Trial end date: 2012-04-12
• Target enrollment: 0
• Participant gender: Male

Summary

This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the amount of drug in the blood. The study will involve healthy male volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Rolipram

Criteria

Inclusion Criteria:

• Healthy male volunteer, aged 22-55 years.

• Normal blood pressure, laboratory values, and body mass index

• Willing to agree to study procedures & contraception requirements

• Capable of giving written informed consent

Exclusion Criteria:

• Any evidence of disease that would preclude participation in the clinical study (includes sexually transmitted diseases, exessive alcohol consumption, and substance abuse).

• Previously involved in another clinical trial within 3 months prior to scheduled administration of study drug

• Smoker

• Suffers from claustrophobia

• Any contraindications for MRI scanning (e.g. pacemaker, metal implants or fillings)